Baird Rates Larimar Therapeutics (LRMR) buy, $5 Price Target

Baird maintains its 'buy' rating on Larimar Therapeutics, targeting $5 per share, a 63.93% upside from the current price.

By TradeTexts Research Desk · Published Jul 1, 2026, 3:02 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Baird rated Larimar Therapeutics, Inc. ($LRMR) "buy" with a $5 price target on June 30, 2026.

Since the rating, $LRMR is up 11.8% after 1 week, up 25.6% after 1 month and down 34.8% to date (from the $3.05 close on Jun 30, 2026).

LRMR Larimar Therapeutics, Inc.

$1.99 -42.65% year to date

Daily close · Oct 16, 2026

Key Points

Baird reiterated its 'buy' rating for Larimar Therapeutics, Inc. (LRMR) with a price target of $5 as of June 30, 2026.
Baird's $5 price target implies 63.93% upside from Larimar Therapeutics, Inc.'s ($LRMR) current $3.05 share price.
Shares of Larimar Therapeutics traded around $3.20 on Wednesday, with a market cap of approximately $316.8 million.
Larimar Therapeutics saw insider buying in May 2026, while Deerfield Management increased its stake by 5 million shares.

Get $LRMR trade alerts by text

We text you when insiders, Congress or big funds trade $LRMR. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Larimar Therapeutics, Inc. alert may contain errors. Disclosures

On June 30, 2026, Baird reiterated its 'buy' rating for Larimar Therapeutics, Inc. (NasdaqGM: LRMR), setting a price target of $5. Analyst Joel Beatty's reaffirmation comes as the stock traded around $3.20 on Wednesday.

Analyst rating track record

Baird vs. the S&P 500

YTD return +11.58% hypothetical

All-time return +17.20% S&P 500 +29.66%

vs. S&P 500 -12.46% behind the index

Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Larimar Therapeutics

Deerfield Management Company, L.P. increased its stake in Larimar Therapeutics by 5 million shares, bringing its total to 35,606,974 shares valued at about $160.2 million. Blue Owl Capital Holdings LP added 296,317 shares, now holding 7,120,007 shares worth approximately $32.0 million. BlackRock, Inc. also upped its position by 70,597 shares, totaling 3,752,200 shares valued at $16.9 million. Conversely, Millennium Management LLC reduced its holdings by 1,581,086 shares, ending with 3,625,278 shares worth $16.3 million. AIGH Capital Management LLC significantly increased its stake by 1 million shares, now holding 3 million shares valued at $13.5 million.

Larimar Therapeutics, Inc. Stock Down 19.5%

Shares of Larimar Therapeutics, Inc. traded near $3.20 on Wednesday. The company, with a market cap of about $316.8 million, operates in the biotechnology industry with a focus on rare disease treatments. It has a beta of 0.817, indicating lower volatility compared to the market. The stock's 52-week range is between $2.72 and $6.42. Its current ratio is 4.292, and it has a debt-to-equity ratio of 2.391.

12-month forecast

$LRMR price target

Larimar Therapeutics, Inc. daily closes and this analyst's $5 target. Not advice.

Insider Buying and Selling at Larimar Therapeutics, Inc.

In May 2026, several insiders, including Joseph Truitt and Jonathan Leff, each purchased 55,150 shares of Larimar Therapeutics. These transactions were not part of any planned trading scheme and indicate a potential vote of confidence from the insiders.

Analysts Set New Price Targets

On June 30, 2026, Baird maintained its 'buy' rating on Larimar Therapeutics with a $5 price target. Previously, on May 27, 2026, JP Morgan initiated coverage with a 'buy' rating and a $9 target. Wedbush has consistently maintained a 'buy' rating, with targets ranging from $11 to $13 in 2026. The consensus among analysts is a 'strong buy' with an average target price of $15.11 across nine opinions.

About Larimar Therapeutics

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania. It focuses on developing treatments for rare diseases using its unique cell-penetrating peptide technology. The company's lead product candidate, CTI-1601, is currently in Phase 2 OLE clinical trials for treating Friedreich's ataxia, a rare and progressive disease. Dr. Carole S. Ben-Maimon leads the company as CEO, and it employs approximately 71 people.

Bottom Line

Baird's reiteration of its 'buy' rating for Larimar Therapeutics highlights ongoing confidence in the company's potential, especially with its focus on rare diseases. Investors often track such analyst ratings as they provide insights into market expectations. It's important to remember that these ratings and targets reflect analysts' views and are subject to change.